Evidence map›Paper›PMID 36050359›Full record

ArticleScientific reports2022

Lack of extracellular matrix switches TGF-β induced apoptosis of endometrial cells to epithelial to mesenchymal transition.

Anna Ruiz-Mitjana, Raúl Navaridas, Maria Vidal-Sabanés, Aida Perramon-Güell, Andree Yeramian, Isidre Felip, Núria Eritja, Joaquim Egea, Mario Encinas, Xavier Matias-Guiu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Anna Ruiz-Mitjana *Oncologic Pathology Group, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Institut de Recerca Biomèdica de Lleida, IRBLleida, Ed Biomedicina I, Hospital Arnau de Vilanova, Av Rovira Roure, 80, 25198, Lleida, Spain.
Raúl Navaridas *Oncologic Pathology Group, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Institut de Recerca Biomèdica de Lleida, IRBLleida, Ed Biomedicina I, Hospital Arnau de Vilanova, Av Rovira Roure, 80, 25198, Lleida, Spain.
Maria Vidal-SabanésOncologic Pathology Group, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Institut de Recerca Biomèdica de Lleida, IRBLleida, Ed Biomedicina I, Hospital Arnau de Vilanova, Av Rovira Roure, 80, 25198, Lleida, Spain.
Aida Perramon-GüellOncologic Pathology Group, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Institut de Recerca Biomèdica de Lleida, IRBLleida, Ed Biomedicina I, Hospital Arnau de Vilanova, Av Rovira Roure, 80, 25198, Lleida, Spain.
Andree YeramianOncologic Pathology Group, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Institut de Recerca Biomèdica de Lleida, IRBLleida, Ed Biomedicina I, Hospital Arnau de Vilanova, Av Rovira Roure, 80, 25198, Lleida, Spain.
Isidre FelipOncologic Pathology Group, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Institut de Recerca Biomèdica de Lleida, IRBLleida, Ed Biomedicina I, Hospital Arnau de Vilanova, Av Rovira Roure, 80, 25198, Lleida, Spain.
Núria EritjaOncologic Pathology Group, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Institut de Recerca Biomèdica de Lleida, IRBLleida, Ed Biomedicina I, Hospital Arnau de Vilanova, Av Rovira Roure, 80, 25198, Lleida, Spain.
Joaquim EgeaMolecular Developmental Neurobiology Group, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Institut de Recerca Biomèdica de Lleida, IRBLleida, Lleida, Spain.
Mario EncinasDevelopmental and Oncogenic Signaling Group, Departament de Medicina Experimental, Universitat de Lleida, Institut de Recerca Biomèdica de Lleida, IRBLleida, Lleida, Spain.
Xavier Matias-GuiuOncologic Pathology Group, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Institut de Recerca Biomèdica de Lleida, IRBLleida, Ed Biomedicina I, Hospital Arnau de Vilanova, Av Rovira Roure, 80, 25198, Lleida, Spain.
Xavier DolcetOncologic Pathology Group, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Institut de Recerca Biomèdica de Lleida, IRBLleida, Ed Biomedicina I, Hospital Arnau de Vilanova, Av Rovira Roure, 80, 25198, Lleida, Spain. xavi.dolcet@udl.cat.
Biomedical Research Institute of Lleida · ESHospital Universitari Arnau de Vilanova · ESUniversitat de Lleida · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The extracellular matrix and the correct establishment of epithelial cell polarity plays a critical role in epithelial cell homeostasis and cell polarity. In addition, loss of tissue structure is a hallmark of carcinogenesis. In this study, we have addressed the role of extracellular matrix in the cellular responses to TGF-β. It is well known that TGF-β is a double-edged sword: it acts as a tumor suppressor in normal epithelial cells, but conversely has tumor-promoting effects in tumoral cells. However, the factors that determine cellular outcome in response to TGF-β remain controversial. Here, we have demonstrated that the lack of extracellular matrix and consequent loss of cell polarity inhibits TGF-β-induced apoptosis, observed when endometrial epithelial cells are polarized in presence of extracellular matrix. Rather, in absence of extracellular matrix, TGF-β-treated endometrial epithelial cells display features of epithelial-to-mesenchymal transition. We have also investigated the molecular mechanism of such a switch in cellular response. On the one hand, we found that the lack of Matrigel results in increased AKT signaling which is sufficient to inhibit TGF-β-induced apoptosis. On the other hand, we demonstrate that TGF-β-induced epithelial-to-mesenchymal transition requires ERK and SMAD2/3 activation. In summary, we demonstrate that loss of cell polarity changes the pro-apoptotic function of TGF-β to tumor-associated phenotype such as epithelial-to-mesenchymal transition. These results may be important for understanding the dual role of TGF-β in normal versus tumoral cells.

Indexed as

Epithelial-Mesenchymal TransitionExtracellular MatrixTransforming Growth Factor betaApoptosisCarcinogenesisEndometriumEpithelial CellsFemaleHumansTransforming Growth Factor beta

Identifiers

PMID36050359
PMCPMC9437059
OpenAlexW4294082373

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.